High expression of ERCC1 is a poor prognostic factor in Chinese patients with non-small cell lung cancer receiving cisplatin-based therapy

Chinese Journal of Cancer Research

Volumn 22, Issue 4, 2010, Pages 296-302

  Guo, Qing Zhi ^a   Wang, Jie ^a   Bai, Hua ^a   An, Tong Tong ^a   Wu, Meina ^a   Zhao, Jun ^a   Yang, Lu ^a   Duan, Jian Chun ^a   Wang, Yu Yan ^a   Wang, Zhi Jie ^a  

^a PEKING UNIVERSITY CANCER HOSPITAL AND INSTITUTE   (China)

Author keywords

ERCC1; mRNA; NSCLC; Platinum based chemotherapy; Realtime PCR; RRM1

Indexed keywords

CISPLATIN; EXCISION REPAIR CROSS COMPLEMENTING PROTEIN 1; GEMCITABINE; MESSENGER RNA; NAVELBINE; PACLITAXEL; RIBONUCLEOTIDE REDUCTASE; RIBONUCLEOTIDE REDUCTASE M1; UNCLASSIFIED DRUG;

ADULT; ADVANCED CANCER; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER PATIENT; CANCER SURVIVAL; CHINESE; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN TISSUE; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; PROGNOSIS; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; RETROSPECTIVE STUDY; TREATMENT RESPONSE;

EID: 78650852845     PISSN: 10009604     EISSN: 19930631     Source Type: Journal    
DOI: 10.1007/s11670-010-0296-0     Document Type: Article

References (23)

1. Non-small Cell Lung Cancer Collaborative Group. 1995 Chemotherapy in non-small cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomized clinical trials[J] Br Med J 311 899 909
2. D.M. Parkin L. Yang L.D. Li, et al. 2005 Mortality time trends and the incidence and mortality estimation and projection for lung cancer in China[J] Chin J Lung Cancer(in Chinese) 8 274 278
3. G.V. Scagliotti F. De Marinis M. Rinaldi, et al. 2002 Phase III randomized trial comparing three-platinum-based doublets in advanced non-small cell lung cancer[J] J Clin Oncol 20 4285 4291 1:CAS:528:DC%2BD38Xpt1CjtLs%3D 10.1200/JCO.2002.02.068 12409326 (Pubitemid 35266288)
4. P.D. Lawley D.H. Phillips 1996 DNA adducts from chemotherapeutic agents[J] Mutat Res 355 13 40 8781575
5. J.T. Reardon A. Vaisman S.G. Chaney, et al. 1999 Efficient nucleotide excision repair of cisplatin, oxaliplatin, and bis-aceto-ammine- dichlorocyclohexylamineplatinum( IV) (JM216) platinum intrastrand DNA diadducts[J] Cancer Res 59 3968 3971 1:CAS:528:DyaK1MXlsVOltLo%3D 10463593
6. Q. Li J.J. Yu C. Mu, et al. 2000 Association between the level of ERCC-1 expression and the repair of cisplatin-induced DNA damage in human ovarian cancer cells[J] Anticancer Res 20 645 652 1:CAS:528:DC%2BD3cXjsVersLY%3D 10810335
7. R. Metzger C.G. Leichman K.D. Danenberg, et al. 1998 ERCC1 mRNA levels complement thymidylate synthase mRNA levels in predicting response and survival for gastric cancer patients receiving combination cisplatin and fluorouracil chemotherapy [J] J Clin Oncol 16 309 316 1:CAS:528:DyaK1cXmsFeruw%3D%3D 9440758
8. Y. Shirota J. Stoehlmacher J. Brabender, et al. 2001 ERCC1 and thymidylate synthase mRNA levels predict survival for colorectal cancer patients receiving combination oxaliplatin and fluorouracil chemotherapy[ J] J Clin Oncol 19 4298 4304 1:CAS:528:DC%2BD3MXptlGjtLk%3D 11731512
9. M.B. Joshi Y. Shirota K.D. Danenberg, et al. 2005 High gene expression of TS1, GSTP1, and ERCC1 are risk factors for survival in patients treated with trimodality therapy for esophageal cancer[J] Clin Cancer Res 11 2215 2221 10.1158/1078-0432.CCR-04-1387 15788669
10. R.V. Lord J. Brabender D. Gandara, et al. 2002 Low ERCC1 expression correlates with prolonged survival after cisplatin plus gemcitabine chemotherapy in non-small cell lung cancer[J] Clin Cancer Res 8 2286 2291 1:CAS:528:DC%2BD38XmtVWhsLw%3D 12114432
11. G.R. Simon S. Sharma A. Cantor, et al. 2005 ERCC1 expression is a predictor of survival in resected patients with non-small cell lung cancer[J] Chest 127 978 983 10.1378/chest.127.3.978 15764785 (Pubitemid 40775532)
12. P. Ceppi M. Volante S. Novello, et al. 2006 ERCC1 and RRM1 gene expressions but not EGFR are predictive of shorter survival in advanced non-small-cell lung cancer treated with cisplatin and gemcitabine[J] Ann Oncol 17 1818 1825 1:STN:280:DC%2BD28jhtlWhug%3D%3D 10.1093/annonc/mdl300 16980606 (Pubitemid 44884058)
13. Y.G. Goan B. Zhou E. Hu, et al. 1999 Overexpression of ribonucleotide reductase as a mechanism of resistance to 2,2-difluorodeoxycytidine in the human KB cancer cell line[J] Cancer Res 59 4204 4207 1:CAS:528:DyaK1MXlvVSnu7o%3D 10485455
14. C. Dumontet K. Fabianowska-Majewska D. Mantincic, et al. 1999 Common resistance mechanisms to deoxynucleoside analogues in variants of the human erythroleukaemic line K562[J] Br J Haematol 106 78 85 1:CAS:528: DyaK1MXltVKiurc%3D 10.1046/j.1365-2141.1999.01509.x 10444166 (Pubitemid 29343530)
15. M.Y. Cao Y. Lee N.P. Feng, et al. 2003 Adenovirus-mediated ribonucleotide reductase R1 gene therapy of human colon adenocarcinoma[J] Clin Cancer Res 9 4553 4561 1:CAS:528:DC%2BD3sXotVSht78%3D 14555530
16. J.D. Davidson L. Ma M. Flagella, et al. 2004 An increase in the expression of ribonucleotide reductase large subunit 1 is associated with gemcitabine resistance in non-small cell lung cancer cell lines[J] Cancer Res 64 3761 3866 1:CAS:528:DC%2BD2cXksVKgurk%3D 10.1158/0008-5472.CAN-03-3363 15172981 (Pubitemid 38697284)
17. R. Rosell K.D. Danenberg V. Alberola, et al. 2004 Ribonucleotide reductase messenger RNA expression and survival in gemcitabine/cisplatin-treated advanced non-small cell lung cancer patients[J] Clin Cancer Res 10 1318 1325 1:CAS:528:DC%2BD2cXhsVCqu7o%3D 10.1158/1078-0432.CCR-03-0156 14977831 (Pubitemid 38365223)
18. G. Simon A. Sharma X. Li, et al. 2007 Feasibility and efficacy of molecular analysis-directed individualized therapy in advanced non-small cell lung cancer[J] J Clin Oncol. 25 2741 2746 1:CAS:528:DC%2BD2sXosValtLg%3D 10.1200/JCO.2006.08.2099 17602079 (Pubitemid 47123182)
19. Q. Li J.J. Yu C. Mu, et al. 2000 Association between the level of ERCC-1 expression and the repair of cisplatin-induced DNA damage in human ovarian cancer cells Anticancer Res. 20 645 652 1:CAS:528:DC%2BD3cXjsVersLY%3D 10810335
20. A. Westerveld J.H. Hoeijmakers M. van Duin, et al. 1984 Molecular cloning of a human DNA repair gene[J] Nature (Lond.) 310 425 429 1:CAS:528: DyaL2cXlsVGjur0%3D 10.1038/310425a0
21. D.W. Melton A.M. Ketchen F. Nunez, et al. 1998 Cells from ERCC1-deficient mice show increased genome instability and a reduced frequency of S-phase-dependent illegitimate chromosome exchange but a normal frequency of homologous recombination[J] J Cell Sci 111 395 404 1:CAS:528:DyaK1cXhsFCgurc%3D 9427687
22. K.B. Lee R.J. Parker V. Bohr, et al. 1993 Cisplatin sensitivity/ resistance in UV repair-deficient Chinese hamster ovary cells of complementation groups 1 and 3[J] Carcinogenesis (Lond.) 14 2177 2180 1:CAS:528: DyaK2cXpsV2ntA%3D%3D 10.1093/carcin/14.10.2177
23. S.G. Chaney A. Sancar 1996 DNA repair: enzymatic mechanisms and relevance to drug response[J] J Natl Cancer Inst 88 1346 1360 1:CAS:528: DyaK28XmsFOkt7k%3D 10.1093/jnci/88.19.1346 8827012